| Nov 15 |
Q3 2024 Invivyd Inc Earnings Call
|
| Nov 15 |
Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
|
| Nov 14 |
Invivyd, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 14 |
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 14 |
Invivyd GAAP EPS of -$0.51 misses by $0.17, revenue of $9.3M
|
| Nov 14 |
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 14 |
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 12 |
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to ...
|
